Swedish Real World COPD Pneumonia Analysis Backs Symbicort Over Seretide
This article was originally published in The Pink Sheet Daily
COPD stalwarts Symbicort and Seretide never have been compared head-to-head in the clinic but Swedish researchers now have analyzed the pair’s respective association with pneumonia, using Sweden’s modern infrastructure and national databases. The review concluded that the AstraZeneca compound soundly beats GlaxoSmithKline’s, based on real-world evidence.
You may also be interested in...
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.